The clinical and molecular significance associated with STING signaling in breast cancer.
Authors
Parkes, Eileen EHumphries, Matthew P
Gilmore, Elaine
Sidi, Fatima A
Bingham, Victoria
Phyu, Su M
Craig, Stephanie
Graham, Catherine
Miller, Joseph
Griffin, Daryl
Salto-Tellez, Manuel
Madden, Stephen F
Kennedy, Richard D
Bakhoum, Samuel F
McQuaid, Stephen
Buckley, Niamh E
Issue Date
2021-06-25Keywords
BREAST CANCERONCOLOGY
Immunosuppression
Metadata
Show full item recordJournal
NPJ breast cancerDOI
10.1038/s41523-021-00283-zPubMed ID
34172750Item Type
ArticleLanguage
enISSN
2374-4677ae974a485f413a2113503eed53cd6c53
10.1038/s41523-021-00283-z
Scopus Count
Collections
Related articles
- STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
- Authors: Lee SJ, Yang H, Kim WR, Lee YS, Lee WS, Kong SJ, Lee HJ, Kim JH, Cheon J, Kang B, Chon HJ, Kim C
- Issue date: 2021 Jun
- Targeting macrophage priming by polyphyllin VII triggers anti-tumor immunity via STING-governed cytotoxic T-cell infiltration in lung cancer.
- Authors: Yu J, Deng H, Xu Z
- Issue date: 2020 Dec 7
- An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
- Authors: Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C
- Issue date: 2007
- The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells.
- Authors: Vasiyani H, Shinde A, Roy M, Mane M, Singh K, Singh J, Gohel D, Currim F, Vaidya K, Chhabria M, Singh R
- Issue date: 2021 Jun
- The cGAS-STING pathway-related gene signature can predict patient prognosis and immunotherapy responses in prostate adenocarcinoma.
- Authors: Zhuo X, Dai H, Yu S
- Issue date: 2022 Dec 16